India Glycols Q3FY26: Revenue Up 13%, EBITDA Surges 36%, Debt Reduced by ₹582 Cr
India Glycols Limited reported a 13.0% YoY increase in Q3 FY26 net revenue to ₹1,102 Cr and a 36.1% surge in EBITDA to ₹176 Cr. For 9MFY26, revenue grew 11.4% to ₹3,235 Cr, with EBITDA up 28.9% to ₹487 Cr. The company achieved a ₹582 Cr debt reduction, including ₹467 Cr from preferential allotment. A demerger into separate entities is planned.
The substantial revenue and EBITDA growth, coupled with a significant debt reduction and ongoing corporate restructuring (demerger), are material events that will likely have a significant impact on the company's financial health, operational focus, and shareholder value.
The company reported strong double-digit growth in revenue and EBITDA for both the quarter and nine-month period, along with significant debt reduction, indicating a positive financial performance and strategic financial management.
India Glycols Limited (IGL) reported strong financial results for the third quarter and first nine months of FY26, marked by record revenue and EBITDA, alongside a substantial debt reduction.
For Q3 FY26, the company registered a net turnover of ₹1,102 Cr, a 13.0% increase year-on-year, with EBITDA surging by 36.1% to ₹176 Cr. This led to an expansion in EBITDA margin by 277 basis points to 16.0%. Profit After Tax (PAT) grew by 18.9% to ₹68 Cr.
The first nine months of FY26 (9MFY26) saw net revenue rise by 11.4% to ₹3,235 Cr, and EBITDA increased by 28.9% to ₹487 Cr, with the EBITDA margin improving to 15.0%. PAT for the period was up by 23.4% to ₹206 Cr.
Key business segments contributed to this growth. The Bio-Fuel (BF) segment showed a remarkable 45.2% YoY revenue increase in Q3 FY26 to ₹394 Cr, and a 51.2% YoY increase to ₹1,165 Cr in 9MFY26. The Potable Spirits (PS) segment reported a 5.0% YoY revenue growth in Q3 FY26 to ₹345 Cr and a 16.6% YoY growth to ₹1,025 Cr in 9MFY26. The Bio-Based Specialties and Performance Chemicals (BSPC) segment achieved ₹313 Cr revenue in Q3 FY26 and ₹901 Cr in 9MFY26, with notable EBIT margin expansions.
IGL also announced a significant total debt reduction of ₹582 Cr, with ₹467 Cr achieved through a Preferential Allotment and the remainder from internal accruals. The full impact of this interest cost reduction is expected to be reflected in Q4 FY26 results.
The company is pursuing a dual strategy for growth in its Potable Spirits segment, focusing on product innovation, premiumisation, and regional expansion. Furthermore, IGL is progressing with its proposed demerger of its Bio Pharma and Spirits & Biofuel undertakings into separate entities, IGL Spirits Limited and Ennature Bio Pharma Limited, with an appointed date for the scheme of arrangement set for April 1, 2026. The company also successfully completed a preferential allotment of equity shares to raise ₹467 Cr.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.